Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%

First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting

Pfizer reports positive results from Echelon-3 study

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone

Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals

Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department

Imfinzi approved in the US for endometrial cancer

Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy

USFDA inspection of Lupin’s Nagpur injectable facility with zero 483 observations

Honeywell introduces batch historian to digitalize manufacturing operations

New software solution helps manufacturers digitalize and gain insights from data to increase efficiency

Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response

GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation

Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims

Melissa Seymour to join Lilly as executive vice president of Global Quality

Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry

Melissa Seymour to join Lilly as executive vice president of Global Quality

Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry